Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Chief Medical Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 169,628 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 4,221 · Balance 169,628 F1: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 4,221 | $19.11 | $80,676.40 |
DisclosureSEC source: 0002051384-26-000009 · form4-09032026_060906.xml · nonDerivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,628 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 4,222 | $12.61 | $53,227.18 |
DisclosureSEC source: 0002051384-26-000006 · form4-06032026_060605.xml · nonDerivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,849 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,026 | $12.36 | $12,683.00 |
DisclosureSEC source: 0002051384-26-000001 · form4-03032026_060308.xml · nonDerivative · entry 2 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,096 F2 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 58,749 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002051384-26-000001 · form4-03032026_060308.xml · derivative · entry 3 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,749 Underlying: Common Stock · 58,749 shares Expires 2036-02-26 F4 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 109,105 | $0.00 | $0.00 |
DisclosureSEC source: 0002051384-26-000001 · form4-03032026_060308.xml · nonDerivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,122 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| February 27, 2026 Filed Mar 13, 2026 20:15 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 91,520 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002051384-26-000002 · form4a-03132026_040312.xml · derivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,520 Underlying: Common Stock · 91,520 shares Expires 2036-02-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| December 02, 2025 Filed Mar 16, 2026 23:55 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,025 | $29.34 | $30,069.30 |
DisclosureSEC source: 0002051384-26-000003 · form4-03162026_070301.xml · nonDerivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,071 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,015 | $18.86 | $19,146.15 |
DisclosureSEC source: 0001415889-25-023745 · form4-09042025_060908.xml · nonDerivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,017 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 94 | $18.69 | $1,756.95 |
DisclosureSEC source: 0001415889-25-015669 · form4-06042025_070614.xml · nonDerivative · entry 3 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,032 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F4 · price: The weighted average sale price for the transaction reported was $18.691 and the range of prices were between $18.69 and $18.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 660 | $18.15 | $11,978.27 |
DisclosureSEC source: 0001415889-25-015669 · form4-06042025_070614.xml · nonDerivative · entry 2 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,126 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $18.1489 and the range of prices were between $17.62 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 285 | $17.03 | $4,852.98 |
DisclosureSEC source: 0001415889-25-015669 · form4-06042025_070614.xml · nonDerivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,786 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $17.028 and the range of prices were between $16.62 and $17.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $19.91 | $0.00 |
DisclosureSEC source: 0001415889-25-006233 · form4-03032025_050309.xml · derivative · entry 2 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2035-02-26 F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from February 27, 2025. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006233 · form4-03032025_050309.xml · nonDerivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,071 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 90,637 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002823 · form4-02032025_080220.xml · derivative · entry 3 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,637 Underlying: Common Stock · 90,637 shares Expires 2035-01-28 F4 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 53,584 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-002823 · form4-02032025_080220.xml · derivative · entry 2 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,584 Underlying: Common Stock · 53,584 shares Expires 2033-09-13 F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 81,217 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001415889-25-002823 · form4-02032025_080220.xml · derivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,217 Underlying: Common Stock · 81,217 shares Expires 2032-12-14 F1 · derivative.exercise_date: One-fourth of the shares subject to this option shall vest one year after November 14, 2022, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:34 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 90,637 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002484 · form4-01312025_090101.xml · derivative · entry 1 Russell Steven Jon · CIK 0002051384 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,637 Underlying: Class B Common Stock · 90,637 shares Expires 2035-01-28 F1 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.